{"url_path":"/sec/cue/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-224091-index.html","accession_number":"0001193125-26-224091","cik":"0001645460","ticker":"CUE","issuer_name":"Cue Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645460/0001193125-26-224091-index.html","primary_entity_key":"0001645460","primary_entity_name":"Cue Biopharma, Inc."},"word_count":256,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\n \n\nIncorporated by Reference\n\nExhibit\n\nNumber\n\nExhibit Description\n\nFiled\n\nHerewith\n\nForm\n\nExhibit\n\nFiling Date\n\nRegistration/File No.\n\n10.1\n\n[Third Amendment to License Agreement dated January 10, 2026, between Cue Biopharma, Inc. and MIL 40G, LLC](cue-ex10_1.htm)\n\nX\n\n \n\n \n\n \n\n \n\n10.2\n\n[Amended and Restated Executive Employment Agreement, dated March 26, 2026, between Cue Biopharma, Inc. and Lucinda Warren](cue-ex10_2.htm)\n\nX\n\n \n\n \n\n \n\n \n\n10.3\n\n[Separation and Release of Claims Agreement, dated March 23, 2026, between Cue Biopharma, Inc. and Usman Azam](cue-ex10_3.htm)\n\nX\n\n \n\n \n\n \n\n \n\n31.1\n\n[Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934](cue-ex31_1.htm)\n\nX\n\n \n\n \n\n \n\n32.1\n\n[Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](cue-ex32_1.htm)\n\nX\n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\nX\n\n \n\n \n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\nX\n\n \n\n \n\n \n\n \n\n104\n\nThe cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, has been formatted in Inline XBRL.\n\nX\n\n \n\n \n\n \n\n \n\n \n\n# Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.\n\n \n\n48\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n \n\nCue Biopharma, Inc.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDated:  May 14, 2026\n\n \n\nBy:\n\n \n\n/s/ Shao-Lee Lin\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nShao-Lee Lin\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer)\n\n \n\n \n\n49"}